ArticleJournal of extracellular vesicles2025
Signal Amplification for Fluorescent Staining of Single Particles in Liquid Biopsies: Circulating Tumour Cells and Extracellular Vesicles.
Article in Journal of extracellular vesicles, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The 'sugar' side of extracellular vesicle-glycome: a panorama from basic characteristics, deciphering technologies, functions, to applications.Journal of nanobiotechnology · 2026Review
- Signal Amplification for Fluorescent Staining of Single Particles in Liquid Biopsies: Circulating Tumour Cells and Extracellular Vesicles.Journal of extracellular vesicles · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Immunofluorescence (IF) staining represents a convenient and cost-effective approach to analysing single extracellular vesicles (EVs) and identifying subpopulations with specific roles or biological functions. However, the application of the method is challenged by the weak and unstable signals generated by the low abundant markers carried by the vesicles. In this study, we report the development of an IF strategy based on tyramide signal amplification (TSA) that employs tyramide probes for signal enhancement. The technique is first validated on glioblastoma circulating tumour cells (GBM CTCs) and systematically compared with conventional approaches using fluorescently labelled primary and secondary antibodies. Thereafter, the proposed method is adapted, tested and optimised for the multiplexed fluorescent staining of single EVs isolated from the parental GBM CTCs. The results demonstrate specific staining of single EVs by the developed TSA method, highlighting its advantages of amplified (>6×) signal intensities, more stable signals and broader (∼3×) signal dynamic ranges as compared to the conventional fluorescence methods. The developed protocol also supports multiplexing by incorporating a quenching buffer between the different staining colours. Finally, the protocol demonstrates its applicability to CTCs and EVs derived from plasma samples of GBM patients, with easy adaptation to other cancers or proteins of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.